Key points from this report:
- Buy Straumann. The stock is breaking out of a five-week flat base into new highs.
- Reopening play; favorable comps. The company reported 8% organic growth in H2 2020, recovering sharply from the pandemic. The company now expects double-digit growth across all regions in Q1. With easy comps in Q2, it is on track to report 30%+ revenue growth in H1.
- Initial 2021 guidance looks conservative. Based on positive business progress and performance in H2 2020, management guided for high-single-digit organic revenue growth in 2021 and expects improvement in profitability over 2020. This looks conservative given the company and peer’s commentary regarding the rebound in 2021.
- Leadership in the $4B dental implant market. Straumann is the leader in the segment with 27% share, up from 26% in 2019, and ahead of its peers Envista (NVST) and Dentsply Sirona (XRAY) at 17% and 11%, respectively. The company also announced geographic expansion in China to focus on the fast growing non-premium segment.
- Next Catalyst: The company will host its AGM on April 9 and will announce Q1 results on April 29.